Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Leukemia, Myeloid, Accelerated Phase 5Carcinoma, Non-Small-Cell Lung 5Leukemia, Myeloid, Chronic-Phase 4Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Breast Neoplasms 2Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1Philadelphia Chromosome 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Malignant Hepatobiliary Neoplasm 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

ponatinib 1Telemedicine 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Malignant Hepatobiliary Neoplasm × ponatinib × Clear all
NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Mayo Clinic

Phase 2 Completed
12 enrolled 11 charts
Gastrointestinal

Malignant Hepatobiliary Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡